Pardes

Jasper Therapeutics Announces Appointment of Thomas G. Wiggans as Chairperson of the Board of Directors

Retrieved on: 
Wednesday, November 1, 2023
CSU, Eli Lilly and Company, Trial of the century, Sangamo Therapeutics, Trustee, Onyx Pharmaceuticals, Leo Pharma, Acquisition, Connetable (Gatchina), MBA, BIO, CD117, Syndrome, Bachelor of Science in Human Biology, Rest, Growth, Biotechnology Innovation Organization, Risk, Methodist University, Partnership, Southern Methodist University, Pharmacy, Chairperson, Pleasure, University, Eli Lilly, Therapy, Patient, Management, Jasper, Science, Pardes

Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.

Key Points: 
  • Bill Lis is stepping down as Chairperson and will retire from the Board in December of this year.
  • “We are pleased to welcome Tom to our Board as Chairperson.
  • “I will be supporting Tom, Ron, and the rest of Jasper as I transition off the Jasper Board to new company ventures.”
    Mr. Wiggans most recently served as Chairman and CEO of Pardes Biosciences.
  • He began his career with Eli Lilly & Co. Mr. Wiggans is currently on the Board of Directors of Annexon, Inc., and Cymabay Therapeutics Inc.

Brain & Behavior Research Foundation Names Special Olympics International Recipient of 2023 Pardes Humanitarian Prize in Mental Health and Awards Honorary Pardes Prize to Henry Jarecki, M.D

Retrieved on: 
Wednesday, October 4, 2023
Special Olympics, International, Association of Summer Olympic International Federations, Disability, Mental health, IIE, DSM-IV codes, Lead, Institute of International Education, Brain & Behavior Research Foundation, Government, Athlete, Social justice, Stigma, Brain, Pardes, Trustee, Scholar Rescue Fund, Intellectual, Mental, Knowledge, Hospital, Psychiatry, Nursing, Pharmaceutical industry, Entertainment

New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that Special Olympics International is the recipient of the 2023 Pardes Humanitarian Prize in Mental Health.

Key Points: 
  • New York, Oct. 04, 2023 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation today announced that Special Olympics International is the recipient of the 2023 Pardes Humanitarian Prize in Mental Health.
  • An Honorary Pardes Prize Recipient was also announced for 2023 – Henry Jarecki, M.D – for his important contributions to the field of psychiatry and his unique work to preserve academic and scientific freedom.
  • “Special Olympics International is being honored as a beacon of light and equality for its decades of service to adults and children with intellectual disabilities,” said Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation.
  • 2023 Honorary Pardes Humanitarian Prize Recipient Henry Jarecki, M.D.

Pardes Biosciences Announces Closing of Tender Offer

Retrieved on: 
Thursday, August 31, 2023
Intellectual property, SVB Securities, CVR, Sub, COVID-19, Foresite Capital, Expiration date, Mergers and acquisitions, PRDS, Expiration, Cryptocurrency, Pardes

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date).

Key Points: 
  • The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on August 30, 2023 (the Expiration Date).
  • As of the Expiration Date, a total of 37,836,066 shares of Pardes common stock were validly tendered, and not validly withdrawn, representing approximately 60.9% of the outstanding shares of Pardes common stock as of the Expiration Date.
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the offer were satisfied or waived.
  • Following the closing of the tender offer, Merger Sub merged with and into Pardes and all shares of Pardes common stock that had not been validly tendered were converted into the right to receive the Offer Price (the Merger).

MediPacific Offering $2.13 Per Share Plus One Contingent Value Right Per Share in Tender Offer for Pardes Biosciences

Retrieved on: 
Monday, August 28, 2023
Health, COVID-19, General Health, Research, Science, Pharmaceutical, Biotechnology, Transfer, Intellectual property, Communication, CVR, Tripura Merger Agreement, Foresite Capital, Schedule, Mergers and acquisitions, PRDS, Tender, Acquisition, Risk, CVR College of Engineering, ARE, Parent, Security (finance), Cryptocurrency, Eastern Time Zone, Asset purchase agreement, Pardes, Offer

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).

Key Points: 
  • Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).
  • As a result, Pardes stockholders that tender their shares in the Offer will receive (i) $2.13 per share and (ii) one non-transferable CVR per share in accordance with the terms of the Offer.
  • Pardes’ stockholders and other investors can obtain the Tender Offer Statement, the Solicitation/Recommendation Statement, the Schedule 13E-3 and other filed documents for free at the SEC’s website at www.sec.gov .
  • In addition, Pardes’ stockholders may obtain free copies of the Offer materials by contacting Innisfree M&A Incorporated, the information agent for the Offer.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, AEL, PRDS, CELL

Retrieved on: 
Sunday, August 20, 2023
Biogen, Sale, Brookfield (corporation), CELL, Advertising, Fraud, NYSE, Bruker, Security (finance), Pardes

If you are a Reata shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Reata shareholder, click here to learn more about your rights and options .
  • If you are an American Equity shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

MediPacific Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Pardes Biosciences Shares

Retrieved on: 
Thursday, August 17, 2023
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, Transfer, Intellectual property, Communication, Additional Civil Lord of the Admiralty, CVR, Shareholder, Tripura Merger Agreement, Foresite Capital, Schedule, Mergers and acquisitions, PRDS, Tender, Acquisition, Risk, CVR College of Engineering, ARE, Security (finance), Cryptocurrency, Eastern Time Zone, Asset purchase agreement, Pardes, Parent

Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).

Key Points: 
  • Pursuant to the Merger Agreement, on July 28, 2023, Purchaser and Parent commenced a tender offer for any or all of Pardes’ outstanding shares of common stock (the “Offer”).
  • Pursuant to the terms of the Merger Agreement, Parent, Purchaser and Pardes have determined that the Additional Price Per Share, based on Pardes’ expected net cash, is $0.11 per share.
  • Accordingly, the total cash amount that Purchaser will pay pursuant to the terms of the Offer and the Merger Agreement is $2.13 per share.
  • Stockholders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the determination of the Additional Price Per Share or extension of the Offer expiration date.

PARDES BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pardes Biosciences, Inc. - PRDS

Retrieved on: 
Monday, August 7, 2023
Biotechnology, Health, Professional Services, Class Action Lawsuit, Legal, Intellectual property, CVR, COVID-19, Sale, Pardes, KSF

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pardes Biosciences, Inc. (NasdaqGM: PRDS) to MediPacific, Inc.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pardes Biosciences, Inc. (NasdaqGM: PRDS) to MediPacific, Inc.
  • KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates UBA, UBP, PRDS, HCCI, CCF

Retrieved on: 
Sunday, August 6, 2023
Regency Centers, UBA, UBP, Urstadt Biddle Properties, KKR, Sale, Advertising, Chase, Regent, Chase Corporation, Fraud, NYSE, Common, Security (finance), Pardes

If you are an Urstadt Biddle shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Urstadt Biddle shareholder, click here to learn more about your rights and options .
  • If you are a Pardes shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, SCU, INPX

Retrieved on: 
Sunday, July 30, 2023
Aircraft, Fraud, NYSE, Advertising, Sale, Security (finance), Pardes

If you are a Pardes shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Pardes shareholder, click here to learn more about your rights and options .
  • If you are a Sculptor shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCU, PRDS, NLTX, AJX

Retrieved on: 
Tuesday, July 25, 2023
Sale, Advertising, Fraud, NYSE, Security (finance), Pardes

If you are a Sculptor shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Sculptor shareholder, click here to learn more about your rights and options .
  • If you are a Pardes shareholder, click here to learn more about your rights and options .
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.